| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T157 |
0-65 |
Sentence |
denotes |
More effective treatments are still under continuing exploration: |
| T158 |
66-73 |
Sentence |
denotes |
On Jan. |
| T159 |
74-314 |
Sentence |
denotes |
25th, 2020, a joint research team from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and Shanghai Tech University screened and identified 30 potential drugs that are reported to be effective against SARS-CoV-2 [79]. |
| T160 |
315-564 |
Sentence |
denotes |
A high-resolution crystal structure of SARS-CoV-2 coronavirus 3CL hydrolase (Mpro) was announced after the outbreak of COVID-19 in the world [80], and human coronaviruses (HCoVs) have been treated as severe pathogens in respiratory tract infections. |
| T161 |
565-651 |
Sentence |
denotes |
Nelfinavir was predicted to be a potential inhibitor of SARS-CoV-2 main protease [81]. |
| T162 |
652-818 |
Sentence |
denotes |
The first patient in the US had been trial-treated with intravenous remdesivir (a novel nucleotide analogue prodrug in development) due to a severe infection [82,83]. |
| T163 |
819-939 |
Sentence |
denotes |
No adverse reactions were observed during the administration, and the patient’s condition was effectively improved [84]. |
| T164 |
940-1016 |
Sentence |
denotes |
Clinical trials of remdesivir for treatment of COVID-19 just started on Feb. |
| T165 |
1017-1124 |
Sentence |
denotes |
5th and 12th, 2020 in Wuhan and Beijing, respectively, and the experimental results remain unclear [85,86]. |
